This study analysed the efficacy of an angiotensin receptor blocker-based treatment algorithm for achieving goal blood pressure (BP) in patients with stage 1 (systolic BP (SBP) 140–159mmHg or diastolic BP (DBP) 90–99mmHg) or stage 2 (SBP160mmHg or DBP100mmHg) hypertension. In this 24-...
To examine the association between stage 1 hypertension (at baseline and longitudinal change) defined by the 2017 ACC/AHA hypertension guidelines and risk of cardiovascular events in a Chinese Kailuan Cohort. A total of 97,126 active and retired workers
Male sex was reported among cardiovascular risk factors in patients with hypertension. A gradient of progressively higher cardiovascular risk from normal BP to elevated BP and stage 1 or 2 hypertension is consistent across subgroups defined by sex. The estimated prevalence of hypertension is not differ...
The 2017 ACC/AHA hypertension guideline lowers BP thresholds for diagnosis of hypertension from 140/90 mm Hg to 130/80 mm Hg, classifying those with SBP levels between 130 and 139 mm Hg as stage 1 and those with SBP levels of at least 140 mm Hg as stage 2.9 Based on this new crite...
Stage 1 high blood pressure or higher, defined as blood pressure of 140/90 mm Hg or higher regardless of the use of antihypertensive medications; Stage 2 high blood pressure or higher, defined as blood pressure of 160/100 mm Hg or higher regardless of the use of antihypertensive medications;...
In contrast, the residual lifetime risk for stage 2 high blood pressure or higher (≥160/100 mm Hg regardless of treatment) was considerably lower in both sexes in the recent period (35%-57% in 1952-1975 vs 35%-44% in 1976-1998), likely due to a marked increase in treatment of ...
2, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of KBP-5074, on top of current therapy, in patients with stage 3B/4 CKD (estimated glo...
patients with stage 1 to stage 2 (mild to moderate) hypertension, alone or in combination with other antihypertensives, including HCTZ, valsartan or ... ST Duggan,CM Chwieduk,MP Curran - 《Drugs》 被引量: 193发表: 2010年 加载更多来源...
Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T : Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256–261. Article CAS PubMed Google Scholar Suzuki H, Nakamoto H, ...
Stage 1 HT Stage 2 HT 2.6 (0.6) 3.3 (0.6) 6.1 (0.9) 13.1 (1.5) 1.2 (0.3) 1.1 (0.3) 2.8 (0.5) 5.5 (0.8) 1.6 (0.6) 1.8 (1.7) 3.6 (0.7) 8.5 (1.3) 1.0 (0.3) 0.5 (0.2) 1.3 (0.4) 2.2 (0.5) 0.6 (0.3) 1.0 (0.3) 2.2 (0.6) 3.7 (0.8) 0.1 (0.08) 0.4 (0.17) 1.3 ...